Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.
Chou
Wen-Chi
WC
Department of Hematology-Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
Huang
Shiu-Feng
SF
Yeh
Kun-Yang
KY
Wang
Hung-Ming
HM
Liu
Mei-Ying
MY
Hsieh
Jia-Juan
JJ
Cheung
Yun-Chung
YC
Chang
John Wen-Cheng
JW
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007796:Laminectomy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000556:secondary* / Q000601:surgery
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077156:Gefitinib